For comparison, Forxiga (known as Farxiga in the US) was shown in the DAPA-CKD to cut by 39% the risk of kidney disease progression, or death from kidney or cardiovascular causes. The new approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback